Philip Jones

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina, Yuting Sun, Marina Protopopova et al. · Nature Medicine · 2018 · 903 citations · Full text

Medicine, Anti-cancer Agent, Cancer Vulnerability +4

Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases

Armin Lahm, Chantal Paolini, Michele Pallaoro et al. · Proceedings of the National Academy of Sciences · 2007 · 569 citations · Full text

Histone Modifications, Hdac Inhibitors, Epigenetic Change +18

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Timothy A. Yap, Naval Daver, Mikhila Mahendra et al. · Nature Medicine · 2023 · 335 citations · Full text

Hematological Malignancy, Oncology, Biochemistry +8

Discovery of 2-{4-[(3<i>S</i>)-Piperidin-3-yl]phenyl}-2<i>H</i>-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors

Philip Jones, Sergio Altamura, Julia K. Boueres et al. · Journal of Medicinal Chemistry · 2009 · 305 citations · Full text

Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain

Matthew J. Bottomley, Paola Lo Surdo, Paolo Di Giovine et al. · Journal of Biological Chemistry · 2008 · 302 citations · Full text

Histone Modifications, Histone Deacetylases, Class Iia +17